Immedica Acquires Marinus Pharma
11 February 2025 - Immedica Pharma AB (“Immedica”), a leading global rare disease company, announced the completion of the acquisition of Marinus Pharmaceuticals, Inc. (“Marinus”) (Nasdaq: MRNS) through its indirect wholly owned subsidiary Matador Subsidiary, Inc., a Delaware corporation (“Purchaser”)
Following the completion of Immedica’s successful tender offer to purchase all outstanding shares of common stock of Marinus for USD 0.55 per share, net to the seller thereof in cash (the “Offer Price”), without interest and subject to any applicable withholding taxes, Immedica acquired all remaining shares of common stock of Marinus through a merger pursuant to Section 251(h) of the General Corporation Law of the State of Delaware. As a result of the transaction, Marinus has become an indirect wholly owned subsidiary of Immedica, and the common stock of Marinus will cease to be traded on the Nasdaq Global Market.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins